Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Two-Drug combo could supercharge deworming in african kids

NCT ID NCT06282315

Prevention Sponsor: Insud Pharma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This large Phase 3 trial in Ghana and Kenya will test whether a single dose of a new albendazole-ivermectin combination pill works better than the standard albendazole alone to prevent soil-transmitted worm infections in 20,000 school-aged children. The study focuses on safety and how well the combo reduces worm infections. If it works, it could improve mass deworming programs across Africa.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
albendazole and ivermectin combination tablet
What this could lead to
If successful, this could provide a more effective single-dose treatment to prevent worm infections in millions of children, reducing disease spread.
What could go wrong
This is a large trial, but the new combination may cause more side effects than the standard drug, and results may vary by region or worm type.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 20,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 to 17 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Individuals of both sexes that attend the selected schools in the trial areas in Ghana and Kenya that meet the following criteria: 1. Age: 5 to 17 years old (included). 2. Height: over 110 cm. 3. Parental acceptance to participate in the study by obtaining written informed consent approved by the Ethics Committee. Written assent will also be obtained from children according to the local national legislation (12-17 years old). Exclusion Criteria: 4. Epidemiological risk of being infected by Loa loa, defined as those who have visited any of the following countries: Angola, Cameroon, Central Africa Republic, Chad, Congo, Democratic Republic of the Congo, Equatorial Guinea, Ethiopia, Gabon, Nigeria and Sudan. 5. Serious medical illness, defined as participants showing symptoms of acute illness which could hamper the participation in the trial, such as high-grade fever, severe diarrhoea, neurological symptoms or others, per investigator's criteria. 6. Any condition prevents the appropriate evaluation and follow-up of the participant, per the investigator's criteria. 7. Known hypersensitivity to any component of either study treatment. 8. Pregnant or first week post-partum: female participants who are post-menarche must have a negative urine pregnancy test at screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Soil-transmitted helminth infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

helminthiasis Hookworm Infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Soil-transmitted helminths

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ghana Health Service (GHS)

    RECRUITING

    Accra, Accra, Ghana

  • Kenya Medical Research Institution (KEMRI)

    RECRUITING

    Nairobi, Nairobi County, 00200, Kenya